Similarly, one BRAF(V600E) splicing variant lacks the binding domain of the RAF inhibitor vemurafenib, leading to acquired drug resistance in melanoma patients with BRAF mutations (Poulikakos et al., 2011). This evidence concerns the gene BRAF and melanoma.